India's own CRISPR cure for sickle cell — at a fraction of the price

Sickle cell disease afflicts millions in India's tribal communities, and Western gene therapies cost crores per patient. CSIR scientists built BIRSA 101 — India's first homegrown CRISPR therapy, editing patients' own stem cells — and partnered with the Serum Institute to make it affordable at national scale.